[1] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies:position paper of the ILAE commission for classification and terminology[J]. Epilepsia, 2017, 58:512-521. [2] Levite M. Autoimmune epilepsy[J]. Nat Immunol, 2002, 3:500. [3] Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61:25-36. [4] Greco A, Rizzo MI, De Virgilio A, Conte M, Gallo A, Attanasio G, Ruoppolo G, de Vincentiis M. Autoimmune epilepsy[J]. Autoimmun Rev, 2016, 15:221-225. [5] Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H; Neuroimaging Committee of the European Association of Nuclear Medicine (EANM), Brain Imaging Council of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15:1009-1010. [6] Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H; European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The need of standardization and of large clinical studies in an emerging indication of[18F]FDG PET:the autoimmune encephalitis[J]. Eur J Nucl Med Mol Imaging, 2017, 44:353-357. [7] Yuan J, Guan H, Zhou X, Niu N, Li F, Cui L, Cui R. Changing brain metabolism patterns in patients with ANMDARE:serial 18F-FDG PET/CT findings[J]. Clin Nucl Med, 2016, 41:366-370. [8] Zhang X, Chen XJ, Li X, Ge JJ, Zuo CT. The 2-[18F] fluoro-2-deoxy-D-glucose PET-CT manifestations of patients with anti-N-methyl-D-aspartate receptorencephalitis at different stages[J]. Zhonghua Shen Jing Ke Za Zhi, 2015, 48:84-88.[张祥, 陈向军,李翔, 葛璟洁, 左传涛. 抗N-甲基-D-天冬氨酸受体脑炎患者不同时期的脑PET-CT显像[J]. 中华神经科杂志, 2015, 48:84-88.] [9] Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A. Decreased occipital lobe metabolism by FDG-PET/CT:an anti-NMDA receptor encephalitis biomarker[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 5:E413. [10] Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, Dalmau J, Gerloff C, Lewerenz J. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis:distinct pattern of disease[J]. J Neurol Neurosurg Psychiatry, 2012, 83:681-686. [11] Moubtakir A, Dejust S, Godard F, Messaoud L, Morland D. 18F-FDG PET/CT in anti-NMDA receptor encephalitis:typical pattern and follow-up[J]. Clin Nucl Med, 2018, 43:520-521. [12] Llorens V, Gabilondo I, Gómez-Esteban JC, Agundez M, Mendibe M, Bergara JC, Ciordia R, Saiz A, Zarranz JJ. Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis[J]. J Neurol, 2010, 257:1568-1569. [13] Finke C, Kopp UA, Scheel M, Pech LM, Soemmer C, Schlichting J, Leypoldt F, Brandt AU, Wuerfel J, Probst C, Ploner CJ, Prüss H, Paul F. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis[J]. Ann Neurol, 2013, 74:284-296. [14] Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels:a case series[J]. Lancet Neurol, 2010, 9:776-785. [15] Shin YW, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Kim TJ, Lee KJ, Kim YS, Park KI, Jung KH, Lee SK, Chu K. VGKC-complex/LGI1-antibody encephalitis:clinical manifestations and response to immunotherapy[J]. J Neuroimmunol, 2013, 265:75-81. [16] Wegner F, Wilke F, Raab P, Tayeb SB, Boeck AL, Haense C, Trebst C, Voss E, Schrader C, Logemann F, Ahrens J, Leffler A, Rodriguez-Raecke R, Dengler R, Geworski L, Bengel FM, Berding G, Stangel M, Nabavi E. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18 F-fluoro-2-deoxy-d-glucose positron emission tomography[J]. BMC Neurol, 2014, 14:136. [17] Kunze A, Drescher R, Kaiser K, Freesmeyer M, Witte OW, Axer H. Serial FDG PET/CT in autoimmune encephalitis with faciobrachial dystonic seizures[J]. Clin Nucl Med, 2014, 39:E436-438. [18] Takkar A, Choudhary A, Ram Mittal B, Lal V. Reversible bilateral striatal hypermetabolism in a patient with leucine-rich glioma inactivated-1 encephalitis[J]. J Clin Neurol, 2016, 12:519-520. [19] He FF, Ye J, Xu WD. Clinical characteristics of leucine-rich glioma-inactivated protein 1 antibody-associated encephalitis[J]. Zhonghua Shen Jing Ke Za Zhi, 2016, 49:26-29.[贺菲菲, 叶静, 徐文灯. 富亮氨酸胶质瘤失活1蛋白抗体脑炎的临床特点[J]. 中华神经科杂志, 2016, 49:26-29.] [20] Heine J, Prüss H, Kopp UA, Wegner F, Then Bergh F, Münte T, Wandinger KP, Paul F, Bartsch T, Finke C. Beyond the limbic system:disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis[J]. J Neurol Neurosurg Psychiatry, 2018, 89:1191-1199. [21] Chen Y, Xing XW, Zhang JT, Wang RX, Zhao W, Tan QC, Liu RZ, Wang XQ, Huang XS, Yu SY. Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease:a retrospective study[J]. J Neuroimmunol, 2016, 295/296:1-8. [22] Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis:correlation with autoantibody types[J]. J Neurol, 2013, 260:2744-2753. [23] Toosy AT, Burbridge SE, Pitkanen M, Loyal AS, Akanuma N, Laing H, Kopelman MD, Andrews TC. Functional imaging correlates of fronto-temporal dysfunction in Morvan's syndrome[J]. J Neurol Neurosurg Psychiatry, 2008, 79:734-735. [24] Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABA(B) receptor in limbicencephalitis with seizures:case series and characterisation of the antigen[J]. Lancet Neurol, 2010, 9:67-76. [25] Kim TJ, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Shin YW, Lee KJ, Jung KH, Kim YS, Park KI, Chu K, Lee SK. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis[J]. J Neuroimmunol, 2014, 270(1/2):45-50. [26] Wang CC, Zhang YX, Yang HL, Wu YY, Shi YY, Gao XY, Xu CS, Zhao JH, Hu YM, Shi XH, Zhang JW. Clinical features of anti γ-aminobutyric acid B receptor encephalitis[J]. Zhonghua Shen Jing Yi Xue Za Zhi, 2017, 16:938-942.[王灿灿, 张元杏,杨辉丽, 吴颖颖, 时英英, 高鑫雅, 徐长水, 赵建华, 胡亚梅, 史晓红, 张杰文. 抗γ-氨基丁酸B受体脑炎临床特点分析[J]. 中华神经医学杂志, 2017, 16:938-942.] [27] Su M, Xu D, Tian R. (18)F-FDG PET/CT and MRI findings in a patient with anti-GABA(B) receptor encephalitis[J]. Clin Nucl Med, 2015, 40:515-517. [28] Ohta K, Seki M, Dalmau J, Shinohara Y. Perfusion IMP-SPECT shows reversible abnormalities in GABA(B) receptor antibody associated encephalitis with normal MRI[J]. Brain Behav, 2011, 1:70-72. [29] Qiao S, Zhang YX, Zhang BJ, Lu RY, Lai QL, Chen LH, Wu J. Clinical, imaging, and follow-up observations of patients with anti-GABAB receptor encephalitis[J]. Int J Neurosci, 2017, 127:379-385. [30] Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Matà S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, BaliceGordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location[J]. Ann Neurol, 2009, 65:424-434. [31] Spatola M, Stojanova V, Prior JO, Dalmau J, Rossetti AO. Serial brain 18 FDG-PET in anti-AMPA receptor limbic encephalitis[J]. J Neuroimmunol, 2014, 271(1/2):53-55. [32] Laurido-Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis[J]. J Neurol, 2019, 266:450-460. [33] Kojima G, Inaba M, Bruno MK. PET-positive extralimbic presentation of anti-glutamic acid decarboxylase antibody-associated encephalitis[J]. Epileptic Disord, 2014, 16:358-361. [34] Ouyang M, Zhou Q, Li H, Hu X, Fei LX, Jin Y, Zhang PQ, Li DF, Li KH, Kuang ZY, Zhou JH. Clinical study of GAD antibody-related autoimmune epilepsy[J]. Dian Xian Yu Shen Jing Dian Sheng Li Xue Za Zhi, 2019, 28:65-71.[欧阳梅, 周青, 李花, 胡湘, 费凌霞, 金洋, 张佩琪, 李淡芳, 李恺辉, 匡祖颖, 周锦华. GAD抗体相关自身免疫性脑炎相关癫痫的临床研究[J]. 癫痫与神经电生理学杂志, 2019, 28:65-71.] |